[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
22-Jun-2014

[ | E-mail ] Share Share

Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society

Denosumab treatment for postmenopausal osteoporosis increases bone density

CHICAGO, IL Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. The results were presented Sunday, June 22, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.

"This study provides reassurance to physicians and their patients that long-term treatment with denosumab for at least 8 years leads to significant increases in bone density and is safe for appropriately selected women with postmenopausal osteoporosis," said lead study author E. Michael Lewiecki, MD, clinical assistant professor of medicine at the University of New Mexico School of Medicine in Albuquerque. "It's important to note that the overall risk of side effects did not increase over time."

Osteoporosis is a long-term disease that occurs when the creation of new bone doesn't keep up with the removal of old bone. The disorder primarily affects women past menopause, causing their bones to become weak and brittle, sometimes so much so that a fall or even a cough can cause a fracture. The treatments that reduce fracture risk by increasing bone density have important long-term effects.

This study showed that long-term treatment with denosumab was safe and resulted in continuing increases in bone density over the 8 years of treatment, with persistently low fracture rates.

To evaluate the long-term efficacy and safety of denosumab for up to 10 years, Dr. Lewiecki and his colleagues conducted the ongoing multinational FREEDOM clinical trial. In this study, the researchers present data from up to 8 years of continued denosumab treatment.

Among the almost 8,000 women originally enrolled in the FREEDOM trial, denosumab reduced their risk of vertebral fractures by 68%, reduced their risk of hip fractures by 40%, and reduced their risk of nonvertebral fractures by 20%, compared with placebo. The women taking the drug had no increase in their overall risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia.

All the roughly 3,000 women in this long-term extension of the trial took denosumab for up to 8 years, and overall, they showed a continued increase in their mean bone mineral density, with a cumulative 8-year gain of 18.4% at the lumbar spine and 8.3% at the total hip, with few fractures and a good safety profile.

###

Amgen Inc. supported the study.

Founded in 1916, the Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society's membership consists of over 17,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.